Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL

Pere Barba • 7 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia Leukemia Blinatumomab CAR-T Inotuzumab ozogamicin Rapcabtagene autoleucel

Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) evaluated in a Phase I trial (NCT03960840). Dr Barba notes that the construct has a manageable safety profile, and the duration and depth of response appear promising. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pere Barba

Future directions for CAR-T in ALL: promising products & strategies being explored 1:11
Future directions for CAR-T in ALL: promising products & strategies being explored
Pere Barba • 7 Feb 2025
Bridging therapy options for patients with ALL & factors influencing bridging therapy selection 0:58
Bridging therapy options for patients with ALL & factors influencing bridging therapy selection
Pere Barba • 7 Feb 2025
Safety & efficacy of obe-cel in R/R ALL: updated findings from the FELIX trial 1:07
Safety & efficacy of obe-cel in R/R ALL: updated findings from the FELIX trial
Pere Barba • 7 Feb 2025
Factors clinicians should consider when selecting patients with ALL for CAR-T therapy 1:04
Factors clinicians should consider when selecting patients with ALL for CAR-T therapy
Pere Barba • 7 Feb 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals